Literature DB >> 19185908

Combined androgen blockade revisited: emerging options for the treatment of castration-resistant prostate cancer.

Matthew N Simmons1, Eric A Klein.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19185908     DOI: 10.1016/j.urology.2008.09.040

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


× No keyword cloud information.
  5 in total

1.  Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer.

Authors:  Minja J Pfeiffer; Frank P Smit; John P M Sedelaar; Jack A Schalken
Journal:  Mol Med       Date:  2011-02-22       Impact factor: 6.354

2.  The curcumin analog ca27 down-regulates androgen receptor through an oxidative stress mediated mechanism in human prostate cancer cells.

Authors:  Alexandra M Fajardo; Debra A MacKenzie; Ming Ji; Lorraine M Deck; David L Vander Jagt; Todd A Thompson; Marco Bisoffi
Journal:  Prostate       Date:  2011-07-27       Impact factor: 4.104

Review 3.  Therapeutic value of quinazoline-based compounds in prostate cancer.

Authors:  Johnathan Bilbro; Matthew Mart; Natasha Kyprianou
Journal:  Anticancer Res       Date:  2013-11       Impact factor: 2.480

4.  Pyridine analogues of curcumin exhibit high activity for inhibiting CWR-22Rv1 human prostate cancer cell growth and androgen receptor activation.

Authors:  Dai-Ying Zhou; Su-Qing Zhao; Zhi-Yun DU; X I Zheng; Kun Zhang
Journal:  Oncol Lett       Date:  2016-05-06       Impact factor: 2.967

5.  Eight-year survival and continuation of therapy in a patient suffering from prostate cancer with metastases and pathological fractures of vertebrae.

Authors:  Sławomir Dutkiewicz; Renata Poniatowska
Journal:  Cent European J Urol       Date:  2011-06-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.